Welcome to our dedicated page for 20/20 Biolabs news (Ticker: AIDX), a resource for investors and traders seeking the latest updates and insights on 20/20 Biolabs stock.
20/20 BioLabs news covers the commercialization of its OneTest laboratory blood-test families, including OneTest for Cancer and OneTest for Longevity. Recurring developments include cancer screening programs, practitioner-channel distribution, AI-enabled chronic disease risk assessment, biomarker technology updates, and laboratory operations tied to its CAP-accredited and CLIA-licensed facility.
Company updates also report financial results, Nasdaq public-company milestones, material license or collaboration agreements, and customer-market activity in public-sector, occupational health, functional medicine, and direct-to-consumer channels.
20/20 BioLabs (Nasdaq: AIDX) reported that its management team participated in BIO Asia-Taiwan from July 15-19 and held strategic meetings in Taipei, Tokyo, and Seoul as part of its East Asia roll-up strategy. The company is evaluating potential merger, acquisition, licensing, joint venture, and commercial partnership opportunities with regional firms whose products, data assets, laboratories, or technology may complement its AI-powered blood tests for early detection and prevention of cancers and chronic diseases.
20/20 BioLabs is targeting businesses with recurring health-check and diagnostics customers, longevity and prevention offerings, commercial infrastructure for products such as OneTest™ for Cancer and OneTest™ for Longevity, and technology or IP that could enhance its AI testing and evidence-generation strategy. Any potential transactions remain subject to due diligence, negotiations, approvals, and regulatory considerations, with no assurance of completion.
20/20 BioLabs (Nasdaq: AIDX) entered a standstill agreement with Streeterville Capital effective July 16, 2026, covering its outstanding Series E Convertible Preferred Stock. For 120 days, Streeterville will not convert preferred shares to common stock unless AIDX trades at least 10% above the Nasdaq “Minimum Price.”
The arrangement is designed to temporarily limit potential dilution from preferred conversions while keeping all existing rights and obligations under the Series E Preferred Stock and related transaction documents otherwise unchanged. After the standstill ends or is terminated, conversions may resume under existing terms.
20/20 BioLabs (Nasdaq:AIDX) highlighted its July 1, 2026 investor webinar, focusing on OneTest™ multi-cancer early detection, Medicare reimbursement strategy, and revenue trends.
The company expects Q2 2026 MCED revenue to be its highest to date and at least 30% above Q2 2025, based on preliminary unaudited data.
Management outlined evidence-generation plans, including real-world data from an expected 35,000 U.S. firefighters tested by end of 2026, and discussed its Longevity platform and M&A focus. Medicare coverage will require future FDA authorization and CMS determinations, which are not yet obtained and are not assured.
20/20 BioLabs (Nasdaq:AIDX) launched a monthly investor webinar series to update shareholders and investors on company developments. The inaugural session will be held on Wednesday, July 1, 2026, at 12:00 p.m. ET.
Webinars will occur on the first Wednesday of each month, last about 45 minutes, and include direct access to management, plus a promotional OneTest discount code for attendees. Replays will be available on the investor relations website.
20/20 Biolabs (Nasdaq:AIDX) announced that its OneTest™ multi-cancer early detection blood test was selected for a Vermont statewide firefighter cancer screening program, covering up to 4,500 firefighters.
The 12‑month initiative is expected to generate about $500,000 in revenues, with options for two additional years.
According to 20/20 Biolabs, Vermont is the second state funding OneTest™, alongside Maryland, where over $500,000 of tests are expected this quarter, just over $400,000 reimbursed by the Maryland Department of Health. Prior year state-funded revenues were about $105,000. A recent federal law enables a Medicare coverage pathway for MCED tests starting in 2028.
20/20 Biolabs (Nasdaq:AIDX) announced contingency planning to add Ebola and Hantavirus PCR testing in its CAP-accredited CLIA lab if public health labs face overflow demand. The company will leverage prior COVID-19 testing experience, when it processed over 400,000 samples during 2021–2022.
The company is assessing global PCR kit suppliers and repurposing existing equipment to expedite assay validation if needed. The announcement does not indicate current regulatory authorization, clinical availability, or a decision to commercialize these tests.
20/20 BioLabs (Nasdaq:AIDX) reported Q1 2026 revenue of $0.4 million, down from $0.6 million in Q1 2025, with gross margin of 17.8% and net loss of $2.2 million.
Cash rose to $4.2 million after a $5.0 million private placement. State-funded firefighter cancer screening programs, new licensing and distribution agreements, and the launch of OneTest™ for Longevity are expected to drive revenue growth from Q2 2026. The company listed on Nasdaq on February 19, 2026, and holds a preferred equity facility of up to $40.0 million, subject to conditions.
20/20 BioLabs (Nasdaq:AIDX) will attend the Sidoti Micro-Cap Virtual Conference on May 20, 2026. CEO Jonathan Cohen will host a presentation from 3:15 PM to 3:45 PM ET in Track 1 and participate in one-on-one investor meetings.
Topics include recently reported quarterly results, recent partnership and licensing activity, and plans to scale the OneTest platform. Investors can access the webcast and schedule meetings through the conference website or conference representatives.
20/20 BioLabs (Nasdaq:AIDX) signed an exclusive worldwide license with the University of South Carolina for a patented PSA velocity algorithm that tracks changes in prostate-specific antigen over time to help flag potentially aggressive prostate tumors earlier.
20/20 plans to integrate the technology into its AI-enabled OneTest for Cancer platform and offer it to other laboratories via software-as-a-service. The partners also anticipate joint research on similar velocity algorithms for markers such as CA 125 and CA 19.9.
20/20 BioLabs (Nasdaq: AIDX) announced that its OneTest™ for Cancer is now available through the Evexia Diagnostics platform, effective April 7, 2026. The collaboration gives OneTest broader visibility across Evexia’s network of ~40,000 functional and integrative medicine practitioners to support adoption and clinical access.
The partnership aims to simplify ordering and integration into clinical workflows while enabling practitioners to use OneTest’s biomarker quantification for baseline and longitudinal patient monitoring.